Nuvation Bio Inc. (NUVB)
NYSE: NUVB · IEX Real-Time Price · USD
2.980
-0.180 (-5.70%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Nuvation Bio Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Nuvation Bio stock have an average target of 6.60, with a low estimate of 5.00 and a high estimate of 10. The average target predicts an increase of 121.48% from the current stock price of 2.98.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 3, 2024.
Analyst Ratings
The average analyst rating for Nuvation Bio stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 3 | 2 | 2 | 2 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 6 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +168.46% | Jun 3, 2024 |
| Wedbush | Wedbush | Buy Reiterates $5 | Buy | Reiterates | $5 | +67.79% | May 24, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +168.46% | May 22, 2024 |
| Wedbush | Wedbush | Buy Reiterates $5 | Buy | Reiterates | $5 | +67.79% | May 15, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $4 → $5 | Buy | Maintains | $4 → $5 | +67.79% | Apr 17, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
841.76K
EPS This Year
-0.28
from -0.35
EPS Next Year
-0.43
from -0.28
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | 3.5M | 31.1M | 127.0M | 347.3M |
| Avg | n/a | 841,755 | 29.5M | 78.6M | 168.7M |
| Low | n/a | n/a | 27.7M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 3,592.9% | 330.1% | 341.6% |
| Avg | - | - | 3,406.1% | 166.5% | 114.5% |
| Low | - | - | 3,190.6% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.21 | -0.40 | -0.45 | -0.32 | -0.46 |
| Avg | -0.28 | -0.43 | -0.46 | -0.38 | -0.45 |
| Low | -0.32 | -0.49 | -0.46 | -0.44 | -0.43 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.